Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2010
09/28/2010US7803817 succinic acid particles or any salts and (ii) hydroxypropyl methyl cellulose phthalate an enteric-coated proton pump inhibitor (PPI) omeprazole; succinic acid particles are released in the stomach in an amount sufficient to reduce gastric acid secretion in conjunction with the PPI; sustained release
09/28/2010US7803816 Melanin-concentrating hormone (MCH) receptor antagonists, such as (S)-2-{(3R,4R)-4-[6-Fluoro-2-(1-hydroxy-1-methyl-ethyl)-5-methyl-benzoimidazol-1-yl]-3 methoxy-piperidin-1-ylmethyl}-indan-5-carbonitrile, useful as dietetics, anxiolytic agents, antidepressants and anorexigenic agents
09/28/2010US7803815 Indol-3-yl-corbonyl-piperidin-benzoimidazol derivatives
09/28/2010US7803814 Tricyclic steroid hormone nuclear receptor modulators
09/28/2010US7803813 selective serotonin receptor agonists, such as 2-chloro-4-fluoro-N-(3-(1-methylpiperidin-4-ylamino)phenyl)benzamide fumarate, used fot the treatment or prevention of neuronal protein extravasation and/or headaches
09/28/2010US7803812 Biphenyl compounds useful as muscarinic receptor antagonists
09/28/2010US7803811 1-methoxy-2-methyl-3-[(4-nitrophenyl)sulphonyl]indolizine, used as angiogenesis inhibitors
09/28/2010US7803810 Inhibitors
09/28/2010US7803809 (2R,3 S)-3 ((2-chloro-4-pyrimidinyl)amino)-4-(3,5-difluorophenyl)-1 (((4'S)-6'-(2,2-dimethylpropyl)-3', 4'-dihydrospiro[cyclobutane-1,2'-pyrano[2,3-b]pyridin]-4'-yl)amino)-2-butanol, used for the treatment Alzheimer's disease, cognitive deficits and impairment, and schizophrenia
09/28/2010US7803808 rapamycin analogues used for inducing immunosuppression, the stimulation of neuron regeneration or the treatment of cancer, fungal infections, transplant rejection, graft vs. host disease, autoimmune disorders, inflammatory and fibrotic diseases, and in the regulation of wound healing
09/28/2010US7803807 such as trans-2-[3'-oxospiro [cyclohexane- 1,1'(3'H)-isobenzofuran]-4yl]-5-(2-pyridyl) imidazo[4,5-b]pyridine, exhibiting neuropeptide Y antagonistic effects, used for the treatment of cardiovascular, nervous system, metabolic, gastrointestinal, sexual and respiratory system disorders; pharmacokinetics
09/28/2010US7803806 protein kinase inhibitors such as 1-{3-[4-(5-Bromo-thiophen-2-yl)-pyrimidin-2-ylamino]-phenyl}-ethanol, used for the treatment of breast cancer or rheumatoid arthritis
09/28/2010US7803805 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl)-3-oxo-propionitrile mono citrate salt; immunosuppressants, autoimmune diseases, skin disorders, Crohn's disease, antidiabetic agents, anticancer agents, antiarthritic agents
09/28/2010US7803804 N,N'-Bis-{4-[N'-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-guanidino]-butyl}terephthalamide, used for the treatment of conditions mediated by the blockade of an epithelial sodium channels
09/28/2010US7803803 Tetrahydrofuro[3,2-B] pyrrol-3-ones as cathepsin K inhibitors
09/28/2010US7803802 used in the treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, and their use as inhibitors of the Human Immunodeficiency Virus, plasmepsins, cathepsin D and protozoal enzymes
09/28/2010US7803801 Spleen tyrosine kinase (syk) inhibitors such as 1-methyl-4-{5-[6-(4-methylpyridin-2-ylamino)pyridin-2-yl]thiazol-2-yl}piperazin-2-one, used for the treatment of allergic or inflammatory diseases
09/28/2010US7803800 Histone deacetylases inhibitors
09/28/2010US7803799 such as 1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-5-(selenophen-2-yl)-1H-pyrazole-3-carboxamide, used for treating cannabinoid-receptor mediated disorders selected from obesity, metabolic syndrome, drug abuse and dependence or neuropathic pain
09/28/2010US7803798 useful in treating vision defects, inflammatory bowel disease, alopecia, the stimulation of hair growth and the stimulation of the conversion of vellus hair to terminal hair
09/28/2010US7803797 Substituted arylcyclopentenes as therapeutic agents
09/28/2010US7803796 Homopiperazine compounds that inhibit ribosomal frameshifting by binding to RNA pseudoknot structure of SARS coronavirus
09/28/2010US7803795 and nitric oxide synthase inhibitor; e.g. 1-(phenylmethyl)-4-piperidyl-6-phthalazine-3one; antiinflammatory agent; preserve the cellular energy level: survival of ischaemic tissues after insult; neurodegenerative diseases: stroke, Alzheimer's and Parkinson's diseases, atherosclerosis, osteoarthritis
09/28/2010US7803794 3-sulfonyl- or 3-amino-lactam derivatives such as (S)-3-(2'-hydroxy-1'-methylcyclohexanecarbonyl)amino-caprolactam, used for treatment of an inflammatory disorders, including amyotropic lateral scelerosis, fibrosis, biological adhesions,antigen induced recall response and immune response suppression
09/28/2010US7803793 For example, 4-(4-Chloro-phenoxy)-N-(1-hydroxy-2-oxo-2,3,4,7-tetrahydro-1H-azepin-3-(R)-yl)-benzenesulfonamide; for treating disorders related to matrix metalloproteases, particularly useful for treating strokes
09/28/2010US7803792 benzothiazepine compounds having a thioamide bond and a quaternary ammonium substituent, exhibiti a potent ileal bile acid transporter inhibiting activity, used for for treating hyperlipidemia or arteriosclerosis
09/28/2010US7803791 biological conjugate drug comprising enzyme inhibitor antibiotics and protein, for the treatment and/or prophylaxis of bacterial inflammatory processes, solid tumor; norfloxacin with albumin; antiinflammatory agents, antitumor agents
09/28/2010US7803790 treating, reducing the frequency of or delaying the onset of pain comprising administering transient receptor potential vanilloid-3 (TRPV3 ) antagonists, such as 2-(6-Amino-benzothiazol-2-ylsulfanyl)-1-(3,4-dihydro-2H-quinolin-1-yl)-ethanone
09/28/2010US7803789 Vitamin D analog—RAK, methods and uses thereof
09/28/2010US7803788 Phosphoramidate linkages; retroviral or hepadnaviral therapy; tissue targeted therapy; HIV/aquired immunodeficiency syndrome; antitumor agents; improved bioavailability
09/28/2010US7803787 Administering a mixture of chondroitin sulfate, n-acetylglucosamine and hyaluronic acid in the absence of a separate analgesic agent for treating connective tissue damage including arthritic disease, osteoarthritis, rheumatoid arthritis, fracture, tendon damage
09/28/2010US7803786 Pharmaceutical co-crystal compositions and related methods of use
09/28/2010US7803785 gemcitabine derivative containing 3* hydroxy-4*-hydroxymethyl substitution in furan ring and pyrimidine ring having substitution HNC(=O)CH3; treat or prevent diseases or disorders such as cancer or viral infections
09/28/2010US7803783 protection of normal cells from cytoreductive therapy that target proliferating cells, by administering modulators of adenomatosis polyposis coli (APC), beta-catenin and Axin signaling pathways; tumor suppressor genes
09/28/2010US7803781 Modulation of growth hormone receptor expression and insulin-like growth factor expression
09/28/2010US7803780 gene therapy of transferring the CD9 gene for suppressing cardiac hypertrophy or cardiac tachycardia in a patient having a heart disease; viral or non-viral expression vector containing a sequence encoding a CD9 protein
09/28/2010US7803779 administering erythromycin derivatives such as 8,9-didehydro-N-demethyl-9-deoxo-6,11-dideoxy-6,9-epoxy-12-O-methyl-N-(1-methylethyl)-11-oxoerythromycin; gastrointestinal disorders
09/28/2010US7803777 conjugates of polyoxyethylene glycol with diverse therapeutic agents, e.g., peptides, lipids, glycolipids and small molecules; utility in biotechnology and medicine
09/28/2010US7803776 Combined use of enzyme inhibitors and of pharmaceutical compositions thereof
09/28/2010US7803766 administering gastrin/(cholecystokinin (CCK) receptor ligand and a factor for complementing gastrin for islet neogenesis therapy; sustained release; for expanding a functional beta cell mass of pancreatic islet transplants; reduces amount of stem cells necessary for treatment; long-acting action
09/28/2010US7803760 Methods of inducing ovulation
09/28/2010US7803748 Nanoparticles for protein drug delivery
09/28/2010US7803622 Adeno-associated virus vectors
09/28/2010US7803611 RNAi expression constructs
09/28/2010US7803602 Method for overexpression of zwitterionic polysaccharides
09/28/2010US7803600 inhibitors of vacuolar-type H+-ATPase; antibiotic; (3Z,5E,7R,8S,9S,11E,13E,15S,16R)-16- [(1S,2R,3S)-3-[(2R,4R,5S,6R)-2,4-dihydroxy-6- isopropyl-5-methyl-2-tetrahydropyranyl]-2- hydroxy-1-methylbutyl]-8-hydroxy-3,15- dimethoxy-5,7,9,11-tetramethyl-1- oxacyclohexadeca-3,5,11,13-tetraen-2-one
09/28/2010US7803577 Polynucleotide encoding a tropoelastin polypeptide; expression products and hybrid molecules of the derivatives and variants
09/28/2010US7803571 Using insulin receptor substrate peptides as diagnostic tool in identifying modulators of protein kinase activity; enzyme inhibitor; mimetics
09/28/2010US7803562 Method for screening human intestinal Npt2B modulatory agents
09/28/2010US7803546 Method of screening for sensitivity to kinase inhibitor therapy
09/28/2010US7803408 Use of human erythropoietin (EPO) to prevent or treat endothelial injury due to chemotherapy, radiation therapy, mechanical trauma, or to a disease state which damages the endothelium
09/28/2010US7803407 Disinfectant and method of making
09/28/2010US7803402 Pharmaceutical preparations
09/28/2010US7803400 Comprised of three lipid elements: phosphatidyl choline, fatty-acyl-cholesterol esters, and at least one apolipoprotein; brain disorders; kits; efficiently target and deliver substances
09/28/2010US7803399 Delivery system for nucleic acids
09/28/2010US7803398 Includes carrier for drug (anticancer agents; anti-sense oligonucleotide against epidermal growth factor receptor) and targeted ligand (benzamide derivative, anisamide) modifying the carrier to target the encapsulated drug to a sigma receptor over-expressed cell
09/28/2010US7803397 Polyethyleneglycol-modified lipid compounds and uses thereof
09/28/2010US7803390 Stable hydroalcoholic compositions
09/28/2010US7803375 Reducing leakage from unwanted choroidal neovasculature by administering an anti-FasL factor to permit an effective amount to localize in the neovasculature, administering a photosensitizer to the neovasculature, and irradiating it with laser light; photodynamic therapy
09/28/2010US7803366 Methods and compositions that enhance bioavailability of coenzyme-Q10
09/28/2010US7803365 Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
09/28/2010US7803354 Cosmetic and/or dermatological use of a composition comprising at least one oxidation-sensitive hydrophilic active principle stabilized by at least one maleic anhydride copolymer
09/28/2010US7803315 Decontamination of surfaces contaminated with prion-infected material with gaseous oxidizing agents
09/28/2010CA2587393C Pharmaceutical manufacturing process
09/28/2010CA2574875C Aryl-pyridine derivatives as 11-beta hsd1 inhibitors
09/28/2010CA2570047C 4-cycloalkoxy benzonitriles as androgen modulators
09/28/2010CA2562992C Probucol analogues, and use thereof as anti-inflammatory inhibitors of vcam-1
09/28/2010CA2553160C 2-heteroaryl-substituted benzimidazole derivative
09/28/2010CA2536929C 2-substituted benzimidazole piperidines analogs as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
09/28/2010CA2527587C Heteroaryl-substituted imidazole derivatives as glutamate receptor antagonists
09/28/2010CA2504614C Process for the preparation of imidazolyl compounds
09/28/2010CA2493765C Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity
09/28/2010CA2481707C Benzopyran derivatives substituted with secondary amines having tetrazole, method for the preparation thereof and pharmaceutical compositions containing them
09/28/2010CA2480065C Injectable veterinary composition for small animals
09/28/2010CA2479640C Hfa suspension formulations containing an anticholinergic
09/28/2010CA2478515C Pharmaceutical preparation containing oxycodone and naloxone
09/28/2010CA2478411C Palatable oral suspension and method
09/28/2010CA2477080C Preparation of prostamides
09/28/2010CA2474430C A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction
09/28/2010CA2470609C Tableted oral pharmaceutical dosage form, with an enteric coating, containing a benzimidazole compound labile in an acid medium
09/28/2010CA2464758C Combination therapy comprising zd6474 and a taxane
09/28/2010CA2464152C Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract
09/28/2010CA2459482C Novel glycolipid and medicine for autoimmune disease containing the same as active ingredient
09/28/2010CA2453881C 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
09/28/2010CA2450915C Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure
09/28/2010CA2449952C Medicinal composition
09/28/2010CA2449485C Pharmaceutical and/or cosmetic compositions for the treatment of localised adiposities and cellulite
09/28/2010CA2448038C Substituted c-furan-2-yl-methylamine and c-thiophen-2-yl-methylamine derivatives
09/28/2010CA2436414C Veterinary dermatologic composition
09/28/2010CA2429267C Cyclohexyl(alkyl)-propanolamines, preparation method and pharmaceutical compositions containing same
09/28/2010CA2415475C Pyrrolo[2,1-b][1,3]benzothiazepines and their use for the preparation of medicaments with antipsychotic activity
09/28/2010CA2407633C Method and compositions for inhibiting arteriosclerosis
09/28/2010CA2395772C Sulfonamide-containing heterocyclic compounds
09/28/2010CA2394090C Oligosaccharide mixture
09/28/2010CA2387016C Acrylamide derivatives as fab i inhibitors
09/28/2010CA2386417C Phenyl- and pyridyl-tetrahydropyridines having tnf-inhibiting activity
09/28/2010CA2383524C Thiazolyl alkynyl compounds and methods of use thereof
09/28/2010CA2383257C Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benozopyrans
09/28/2010CA2382631C Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids
09/28/2010CA2382247C Azaindoles having serotonin receptor affinity